-
公开(公告)号：WO2009118420A9
公开(公告)日：2009-10-01
申请号：PCT/EP2009/053698
申请日：2009-03-27
Applicant: NOVARTIS AG , KOST, Holger , RAMSEGER, Simon
Inventor： KOST, Holger , RAMSEGER, Simon
IPC: G01N27/447
Abstract: The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination.
-
2.发明申请
公开(公告)号：WO2007080123A1
公开(公告)日：2007-07-19
申请号：PCT/EP2007/000272
申请日：2007-01-12
Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC. , KOST, Holger
Inventor： KOST, Holger
IPC: G01N33/569 , C12N7/02
CPC classification number: C12Q3/00 , C12N7/00 , C12N2760/16011 , C12N2760/16111 , C12N2760/16211 , C12Q1/04 , G01N33/56983 , G01N2333/07 , G01N2333/11
Abstract: The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.
Abstract translation: 本发明提供了一种确定样品中病毒颗粒和/或病毒抗原浓度的方法。 特别地，本发明涉及确定样品中流感病毒颗粒/流感病毒抗原的浓度。 本发明还涉及离子交换基质用于测定样品中病毒颗粒和/或病毒抗原浓度的用途。
-
Patent Agency Ranking3.发明申请
公开(公告)号：WO2007052163A3
公开(公告)日：2007-05-10
申请号：PCT/IB2006/003880
申请日：2006-11-01
Inventor： GREGERSEN, Jens-Peter , KOST, Holger
IPC: A61K39/12 , A61K39/145
Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
-
4.发明申请
公开(公告)号：WO2007052163A2
公开(公告)日：2007-05-10
申请号：PCT/IB2006003880
申请日：2006-11-01
Applicant: NOVARTIS VACCINES & DIAGNOSTIC , GREGERSEN JENS-PETER , KOST HOLGER
Inventor： GREGERSEN JENS-PETER , KOST HOLGER
IPC: A61K39/00
CPC classification number: C12N7/00 , A61K39/12 , A61K39/145 , A61K2039/5252 , C12N2760/16134 , C12N2760/16151 , C12N2760/16234
Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ß-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
Abstract translation: 本发明涉及用于治疗或预防病毒感染的疫苗产品。 还提供了减少与细胞培养疫苗的制备相关的污染物的方法。 残余功能细胞培养物DNA通过用DNA烷基化剂如β-丙内酯（BPL）处理而降解，由此提供一种疫苗，其包含衍生自在细胞培养物上繁殖的病毒的基本上没有残留的功能性细胞培养物DNA的免疫原性蛋白质。
-
公开(公告)号：WO2009118420A1
公开(公告)日：2009-10-01
申请号：PCT/EP2009053698
申请日：2009-03-27
Applicant: NOVARTIS AG , KOST HOLGER , RAMSEGER SIMON
Inventor： KOST HOLGER , RAMSEGER SIMON
IPC: G01N27/447
CPC classification number: G01N27/44743
Abstract: The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination.
Abstract translation: 本发明涉及检测核酸的方法，其中待分析的核酸存在的样品通过毛细管电泳分离。 样品注射和分离的条件允许该方法的极高的灵敏度，其可以应用，例如。 用于质量控制目的，用于测定包含用于治疗或接种疫苗的蛋白质的样品中基因组DNA污染物的存在，数量和/或尺寸。
-
6.发明申请
公开(公告)号：WO2007085969A3
公开(公告)日：2007-12-27
申请号：PCT/IB2007001150
申请日：2007-01-26
Applicant: NOVARTIS VACCINES & DIAGNOSTIC , BROEKER MICHAEL , KOST HOLGER
Inventor： BROEKER MICHAEL , KOST HOLGER
IPC: A61K39/145
CPC classification number: A61K39/145 , A61K39/12 , A61K2039/55566 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/16122 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171 , C12N2760/16222 , C12N2760/16234
Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.
Abstract translation: 包含流感病毒血细胞凝集素和基质蛋白的免疫原性组合物。 这些可能来自在细胞培养而不是鸡蛋中生长的流感病毒。 基质蛋白可以是全长病毒基质蛋白的片段，例如， 分子量小于20kDa的矩阵M1片段。 组合物可以是包含纯化的表面糖蛋白的亚单位疫苗。
-
公开(公告)号：WO2007085969A2
公开(公告)日：2007-08-02
申请号：PCT/IB2007/001150
申请日：2007-01-26
Inventor： BROEKER, Michael , KOST, Holger
CPC classification number: A61K39/145 , A61K39/12 , A61K2039/55566 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/16122 , C12N2760/16134 , C12N2760/16151 , C12N2760/16171 , C12N2760/16222 , C12N2760/16234
Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.
Abstract translation: 包含流感病毒血细胞凝集素和基质蛋白的免疫原性组合物。 这些可能来自细胞培养中生长的流感病毒而不是卵子。 基质蛋白可以是全长病毒基质蛋白的片段，例如 分子量小于20kDa的基质M1片段。 该组合物可以是包含纯化表面糖蛋白的亚单位疫苗。
-
-
-
-
-
-
Search Results
7
records
(took 0.012 seconds)
